Leo Cancer Care, a pioneer in radiotherapy treatment devices, announced the successful raise of approximately $40 million in a funding round led by Catalio Capital Management. The round also saw participation from new and existing investors.

This substantial investment will accelerate the commercialization of Leo Cancer Care's next-generation upright radiotherapy system, designed to enhance patient outcomes and broaden access to advanced cancer treatment. As part of the funding round, Catalio's Dr. Nicholas von Guionneau joins Leo Cancer Care's board as an Observer.

Stephen Towe, Co-Founder and CEO of Leo Cancer Care, commented, "We are very excited to welcome Catalio as an investor. The trust and support of new and returning investors highlight the growing recognition of upright radiotherapy's potential to improve patient experiences and expand access to advanced treatments globally."

Dr. von Guionneau added, "Leo Cancer Care has created a new technology platform centered on upright patient positioning that unlocks a pipeline of pioneering therapeutic and diagnostic products. These have immense potential to improve patient care. Catalio is proud to support Leo's mission through its proton therapy expansion and upcoming debut in photon therapy."

Leo Cancer Care's first product, Marie, named after physicist Marie Curie, is an upright patient positioning system and CT scanner for proton therapy that replaces gantry rotation with patient rotation. Marie reduces the size, cost, and complexity of proton therapy, making these treatments more patient-friendly and globally accessible.

Marie recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA), and multiple leading cancer centers in the U.S. have already installed the technology. The first patient treatments are anticipated later in 2025.